PL4053126T3 - Pochodna mostkowana cykloformylopirydyny i jej zastosowanie - Google Patents
Pochodna mostkowana cykloformylopirydyny i jej zastosowanieInfo
- Publication number
- PL4053126T3 PL4053126T3 PL20881576.1T PL20881576T PL4053126T3 PL 4053126 T3 PL4053126 T3 PL 4053126T3 PL 20881576 T PL20881576 T PL 20881576T PL 4053126 T3 PL4053126 T3 PL 4053126T3
- Authority
- PL
- Poland
- Prior art keywords
- cycloformylpyridine
- bridged
- derivative
- application
- cycloformylpyridine derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911061801.8A CN112759593A (zh) | 2019-11-01 | 2019-11-01 | 桥环并醛基吡啶衍生物及其应用 |
| PCT/CN2020/122569 WO2021083011A1 (zh) | 2019-11-01 | 2020-10-21 | 桥环并醛基吡啶衍生物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4053126T3 true PL4053126T3 (pl) | 2026-03-16 |
Family
ID=75692356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20881576.1T PL4053126T3 (pl) | 2019-11-01 | 2020-10-21 | Pochodna mostkowana cykloformylopirydyny i jej zastosowanie |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12344611B2 (pl) |
| EP (1) | EP4053126B1 (pl) |
| JP (1) | JP7349572B2 (pl) |
| KR (1) | KR102779260B1 (pl) |
| CN (2) | CN112759593A (pl) |
| AU (1) | AU2020375960B2 (pl) |
| ES (1) | ES3057523T3 (pl) |
| PL (1) | PL4053126T3 (pl) |
| WO (1) | WO2021083011A1 (pl) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009046141A2 (en) | 2007-10-01 | 2009-04-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
| SG11201500125QA (en) | 2012-07-11 | 2015-02-27 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| CN105392788B (zh) * | 2013-05-13 | 2018-10-23 | 葛兰素史密斯克莱有限责任公司 | 用作沉默调节蛋白调节剂的取代的桥连脲类似物 |
| RS63405B1 (sr) | 2013-10-25 | 2022-08-31 | Blueprint Medicines Corp | Inhibitori receptora faktora rasta fibroblasta |
| US20160115164A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CN107304210A (zh) * | 2016-04-25 | 2017-10-31 | 成都融科博海科技有限公司 | 一种选择性fgfr4激酶抑制剂 |
| SG11201903911UA (en) | 2016-11-02 | 2019-05-30 | Novartis Ag | Combinations of fgfr4 inhibitors and bile acid sequestrants |
| CN109745321B (zh) | 2017-11-08 | 2022-04-29 | 上海翰森生物医药科技有限公司 | 包含fgfr4抑制剂的药物组合物 |
-
2019
- 2019-11-01 CN CN201911061801.8A patent/CN112759593A/zh active Pending
-
2020
- 2020-10-21 EP EP20881576.1A patent/EP4053126B1/en active Active
- 2020-10-21 KR KR1020227017542A patent/KR102779260B1/ko active Active
- 2020-10-21 JP JP2022525663A patent/JP7349572B2/ja active Active
- 2020-10-21 AU AU2020375960A patent/AU2020375960B2/en active Active
- 2020-10-21 WO PCT/CN2020/122569 patent/WO2021083011A1/zh not_active Ceased
- 2020-10-21 PL PL20881576.1T patent/PL4053126T3/pl unknown
- 2020-10-21 ES ES20881576T patent/ES3057523T3/es active Active
- 2020-10-21 US US17/755,337 patent/US12344611B2/en active Active
- 2020-10-21 CN CN202080075456.8A patent/CN114650991B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230012600A1 (en) | 2023-01-19 |
| EP4053126A1 (en) | 2022-09-07 |
| CN114650991A (zh) | 2022-06-21 |
| ES3057523T3 (en) | 2026-03-03 |
| EP4053126C0 (en) | 2025-11-19 |
| CN112759593A (zh) | 2021-05-07 |
| WO2021083011A1 (zh) | 2021-05-06 |
| KR102779260B1 (ko) | 2025-03-11 |
| JP7349572B2 (ja) | 2023-09-22 |
| KR20220088909A (ko) | 2022-06-28 |
| AU2020375960B2 (en) | 2023-07-20 |
| JP2023501288A (ja) | 2023-01-18 |
| CA3156615A1 (en) | 2021-05-06 |
| US12344611B2 (en) | 2025-07-01 |
| EP4053126A4 (en) | 2022-12-14 |
| CN114650991B (zh) | 2024-10-18 |
| AU2020375960A1 (en) | 2022-06-09 |
| EP4053126B1 (en) | 2025-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292161A (en) | New methylquinazolinone derivatives | |
| EP3994692C0 (en) | BINARY COMPUTING CELL IN MEMORY | |
| DK4067344T3 (da) | Cycloalkylurinstofderivat | |
| IL282998A (en) | Pyridazinone compounds and uses thereof | |
| EP4281085A4 (en) | MODIFIED DOUBLE-STRANDED OLIGONUCLEOTIDES | |
| EP3845532A4 (en) | QUINOLINO-PYRROLIDIN-2-ONE DERIVATIVE AND APPLICATION THEREOF | |
| IL278122B1 (en) | Pteridinone compounds and uses thereof | |
| DK4018074T3 (da) | Borebrøndindretning | |
| PL4013751T3 (pl) | Pochodne 2-hydroksycykloalkano-1-karbamoilu | |
| EP3930851A4 (en) | COMBINATION THERAPIES | |
| EP3919491C0 (en) | AKT INHIBITOR | |
| EP4077334C0 (en) | FUROINDAZOLE DERIVATIVES | |
| EP4021904C0 (en) | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | |
| EP3967649C0 (en) | LIPID NANOPARTICLE | |
| EP3742771C0 (en) | M2M SM-SR TO SM-DP NOTIFICATION | |
| IL285118A (en) | Compounds and uses thereof | |
| EP4069242A4 (en) | Combinations | |
| PT4011898T (pt) | Derivado de 3-hidroxi-5-pregnano-20-ona e sua utilização | |
| EP3912517C0 (en) | FRAME | |
| EP3973348A4 (en) | HEAD MOUNT DISPLAYS | |
| EP3975220A4 (en) | Display panel | |
| DK4064937T3 (da) | Møbelsæt | |
| EP3999703A4 (en) | A hinge joint | |
| EP3965638C0 (en) | VAGINAL SPECULUM | |
| EP3962498A4 (en) | Combination therapies |